# US 7,608,284 B2 · Enamel matrix protein composition for treatment of systemic inflammatory response syndrome > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,608,284 B2 - Document ID: US7608284B2 - Status: Granted - Kind: B2 - Application number: 10/242,684 - Filed: 2002-09-12 - Published: 2003-04-24 - Granted: 2009-10-27 - Earliest claimed: 2001-09-14 - Assignees: Institut Straumann AG - Inventors: Stina Gestrelius; Petter Lyngstadaas - Web page: https://patentgrep.com/patent/US7608284B2 ## CPC - A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane - A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 5/00: Drugs for disorders of the endocrine system - A61P 5/40: Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids - A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 11/00: Drugs for disorders of the respiratory system - A61P 11/06: Antiasthmatics - A61P 17/00: Drugs for dermatological disorders - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 17/06: Antipsoriatics - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 21/04: for myasthenia gravis - A61P 25/00: Drugs for disorders of the nervous system - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 31/12: Antivirals - A61P 37/02: Immunomodulators - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease. ## Claims ### Claim 1 A method of treating a mammal for systemic inflammatory response syndrome, said method comprising administering parenterally to said mammal a composition comprising from 0.1 mg/mL to 1 mg/mL enamel matrix proteins having a weight ratio of about 80/8/12 between main protein peaks at 20, 14, and 5 kDa, respectively. ### Claim 2 (depends on 1) The method according to claim 1, wherein the systemic inflammatory response syndrome results from shock, burns, extensive surgical procedures, traumatic injury, dialysis, and bacterial or viral infection. ### Claim 3 (depends on 1) The method according to claim 1, wherein the systemic inflammatory response syndrome results from a disease selected from the group consisting of extracorporeal membrane oxygenation, shock, systemic inflammatory response syndrome, sepsis, multi organ failure, rejection of an implant such as an organ or prosthesis, heart and lung bypass surgery, chronic inflammation, asthma, stress related disease in the lung, gangrene, soft tissue infection and wound infection. ### Claim 4 (depends on 1) The method according to claim 1, wherein the systemic inflammatory response syndrome is caused by a bacterium selected from the group consisting of gram negative microbes and gram positive microbes. ### Claim 5 (depends on 4) The method according to claim 4, wherein said systemic inflammatory response syndrome is caused by an endo-toxin or an exo-toxin produced by said microbe. ### Claim 6 (depends on 5) The method according to claim 5, wherein the systemic inflammatory response syndrome is caused by PepG from Staphylococcus aureus. ### Claim 7 (depends on 5) The method according to claim 5, wherein the systemic inflammatory response syndrome is caused by an LPS from Escherichia coli. ### Claim 8 (depends on 1) The method according to claim 1, wherein the enamel matrix proteins are of porcine origin. ### Claim 9 (depends on 1) The method according to claim 1, wherein the enamel matrix proteins are of synthetic origin. ### Claim 10 (depends on 1) The method according to claim 1, wherein the mammal is human. ### Claim 11 (depends on 1) The method according to claim 1, wherein the enamel matrix proteins comprise one or more of the following: amelogenins, proline-rich non-amelogenins, tuftelins, tuft proteins, serum proteins, salivary proteins, ameloblastins, sheathlins, and mixtures thereof. ### Claim 12 (depends on 1) The method according to claim 1, wherein the enamel matrix proteins comprise amelogenins. ### Claim 13 (depends on 1) The method according to claim 1, wherein the enamel matrix proteins comprise one or both of proline-rich proteins or poly-proline proteins. ### Claim 14 (depends on 1) The method according to claim 1, wherein the composition comprising enamel matrix proteins is administered by continuous injection. ### Claim 15 (depends on 1) The method according to claim 1, wherein the composition comprising enamel matrix proteins is administered as a bolus injection. ### Claim 16 (depends on 1) The method according to claim 1, wherein the composition comprises a pharmaceutically acceptable excipient. ### Claim 17 (depends on 16) The method according to claim 16, wherein the pharmaceutically acceptable excipient is phosphate buffer saline. ### Claim 18 (depends on 1) The method according to claim 1, further comprising administering one or more active drug substances with said composition comprising enamel matrix proteins. ### Claim 19 (depends on 18) The method according to claim 18, wherein the one or more active drug substances are independently selected from the group consisting of: anti-bacterial, anti-inflammatory, antiviral, antifungal, inducers of apoptosis, growth factors, keratinocyte growth factors, and peptide analogs thereof. ### Claim 20 (depends on 1) The method of claim 1, wherein the composition is administered in combination with local chemotherapy.